Provided by Tiger Trade Technology Pte. Ltd.

Gyre Therapeutics

6.90
+0.17002.53%
Volume:25.53K
Turnover:174.53K
Market Cap:769.42M
PE:-36.25
High:6.92
Open:6.82
Low:6.75
Close:6.73
52wk High:9.42
52wk Low:5.44
Shares:111.51M
Float Shares:35.93M
Volume Ratio:0.72
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1903
EPS(LYR):0.0225
ROE:-17.44%
ROA:-5.42%
PB:7.13
PE(LYR):306.88

Loading ...

Top Gyre Therapeutics Executive Makes Surprise Stock Move

TIPRANKS
·
Jun 23

Gyre Therapeutics COO Ye Weiguo disposes of USD 87,450 common shares

Reuters
·
Jun 23

Gyre Therapeutics Shareholders Approve Directors and Governance Measures

TIPRANKS
·
Jun 16

Gyre Therapeutics shareholders elect directors at annual meeting

Reuters
·
Jun 16

Top Executive Makes Notable Move With Gyre Therapeutics Stock

TIPRANKS
·
Jun 16

Gyre COO Weiguo Ye disposes of 2,800 common shares for $17,276

Reuters
·
Jun 16

Gyre Therapeutics COO Ye Weiguo sells USD 129,295 of common shares

Reuters
·
Jun 12

Top Executive’s Bold Move at Gyre Therapeutics Stirs Investor Buzz

TIPRANKS
·
Jun 09

Gyre Therapeutics COO Ye Weiguo disposes of USD 217,732 of common shares

Reuters
·
Jun 09

Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy

TIPRANKS
·
Jun 02

Gyre Therapeutics publishes corporate presentation on fibrosis, inflammatory disease and cancer pipeline

Reuters
·
Jun 02

Gyre Therapeutics COO Weiguo Ye sells 7,500 common shares for $45,690.35

Reuters
·
May 28

Gyre COO Ye Weiguo disposes of 22,220 shares worth $136,653

Reuters
·
May 23

Gyre COO Ye Weiguo sells USD 59,833 Gyre Therapeutics shares

Reuters
·
May 21

Gyre COO Weiguo Ye disposes 28,680 shares for $193,510.3

Reuters
·
May 19

Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion

TIPRANKS
·
May 15

Gyre Therapeutics announces China NMPA acceptance of F351 NDA

TIPRANKS
·
May 13

China NMPA accepts Gyre NDA for hydronidone in hepatitis B liver fibrosis

Reuters
·
May 13

Gyre Therapeutics Announces Nmpa Acceptance of New Drug Application for F351 (Hydronidone) for Chb-Induced Liver Fibrosis Treatment

THOMSON REUTERS
·
May 13

Gyre Therapeutics: Plans to File Ind Application in U.S. by 2026 End; IF Ind Becomes Effective, to Initiate Phase 2 Clinical Trial

THOMSON REUTERS
·
May 13